Clinical Trial Nuedexta in Subjects With ALS

Center for Neurologic Study, La Jolla, California,90 enrolled

Overview

The purpose of this study is to determine whether Nuedexta is effective in the treatment of symptoms (impaired speech, swallowing, and saliva control)associated with Amyotrophic Lateral Sclerosis (ALS).

Muscle weakness, the cardinal feature of ALS, leads to progressive loss of motor function affecting the limbs, tongue, respiratory and pharyngeal muscles. Symptomatic treatments such as the placement of a feeding tube, can compensate for the inability to swallow. Riluzole, the only approved treatment for ALS, may slow disease progression but no treatment is curative and none have improved function. Unexpectedly, Nuedexta®, approved for the treatment of labile emotionality that occurs in association with ALS and other neurological disorders, has been observed to improve bulbar function, primarily speech and swallowing, in a number of neurological disorders, including ALS. The basis for this is conjectural but likely due to a direct effect of the drug on motor neurons in the part of the brain that controls speech and swallowing. The same part of the brain appears to modulate the expression of emotions and interestingly the site of action of the drug is the same as a site that has been implicated in a juvenile form of ALS. This is a multicenter, randomized double-blind, placebo controlled, cross over study evaluating the palliative effect of Nuedexta® on bulbar dysfunction. It is expected that approximately 60 ALS patients from 7 clinical centers in the US will be enrolled.

Study Type

INTERVENTIONAL

Allocation

RANDOMIZED

Purpose

TREATMENT

Masking

DOUBLE

Enrollment

Conditions

Amyotrophic Lateral Sclerosis (ALS)

Interventions

NuedextaDRUG

Nuedexta PO (by mouth) for 28 ± 3 days

Matching PlaceboDRUG

matching placebo PO (by mouth) for 28 ± 3 days

Eligibility

Sex: ALLMin age: 18 Years

Medical Language ↔ Plain English

Inclusion Criteria: * ALS diagnosed as possible, laboratory-supported probable, probable, or definite as defined by revised El Escorial criteria * Age 18 years or older * Exhibits bulbar dysfunction manifested by dysarthria and/or dysphagia, according to PI judgment, exhibits a score of 55 or above on the CNS-Bulbar Function Scale * Capable of providing informed consent and following trial procedures * Geographic accessibility to the site * Women must not be able to become pregnant for the duration of the study and must be willing to be on two contraceptive therapies * Slow vital capacity (SVC) measure ≥50% of predicted for gender, height, and age at the screening visit * Must be able to swallow capsules throughout the course of the study, according to PI judgment * Subjects must not have taken riluzole for at least 30 days or be on a 50mg BID dose of riluzole for at least 30 days prior to randomization (subjects how have never taken riluzole are permitted in the study) * Subjects taking anti-sialorrhea medication(s) must be on a stable dose for at least 30 days prior to randomization (anti-sialorrhea naïve subjects are permitted in the study) * Must be able to safely swallow at least 30 milliliters (mLs) of water for the water swallowing test Exclusion Criteria: * Prior use of Nuedexta® * Current use of dextromethorphan, quinidine, quinine, mefloquine or opioids * History of quinidine, quinine, or mefloquine-induced thrombocytopenia, hepatitis, or other hypersensitivity reactions * History of known sensitivity or intolerability to dextromethorphan * Use of an mono amine oxidase inhibitor (MAOI) or within 14 days of stopping an MAOI * Prolonged QT interval, congenital long QT syndrome, history suggestive of torsades de pointes, or heart failure * Complete atrioventricular (AV) block without implanted pacemaker, or subjects at high risk of complete AV block * Concomitant use with drugs that both prolong QT interval and are metabolized by cytochrome P 2D6 (CYP2D6) (i.e., thioridazine or pimozide) * Exposure to any other experimental agent (off-label use or investigational) within 30 days prior to Baseline Visit * Invasive ventilator dependence, such as tracheostomy * Any history of either substance abuse within the past year, unstable psychiatric disease, cognitive impairment, or dementia, according to PI judgment * Placement and/or usage of feeding tube * Pregnant women or women currently breastfeeding * Unable to turn diaphragm pacing device off during swallowing tests * Salivatory Botox within 90 days (3 months) of screening * Salivatory radiation within 180 days (6 months) of screening

Locations (7)

California Pacific Medical Center

San Francisco, California, United States

Georgetown University Medical Center

Washington D.C., District of Columbia, United States

Saint Mary's Health Care

Grand Rapids, Michigan, United States

Hennepin County Medical Center

Minneapolis, Minnesota, United States

Outcomes

Primary Outcomes

Bulbar Function Scale (CNS-BFS) Total Score

The Center for Neurologic Study-Bulbar Function Scale (CNS-BFS) is a 21-item self report scale that assesses three domains of bulbar function: speech, swallowing and salivation. Scores for each question range from 1 (does not apply) to 5 (applies most of the time). The higher the score, the worse the speech, swallowing and salivation (sialorrhea). \[Range of score: 21-105\] The scale was modeled on the Center for Neurologic Study Emotional Lability Scale (CNS-LS) that has been a robust endpoint in four clinical trials. The scale was validated in a large population of ALS patients (n=122) and detects impaired bulbar function at a sensitivity of 90% and a specificity of 0.97%. Test re-test correlation was 0.92% at six-months (n=53).

Time frame: Average between Screening Visit to Visit 3

Bulbar Function Scale (CNS-BFS) Sialorrhea Score

Time frame: Average between Screening Visit to Visit 3

Bulbar Function Scale (CNS-BFS) Speech Score

Time frame: Average between Screening Visit to Visit 3

Bulbar Function Scale (CNS-BFS) Swallowing Score

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.

Secondary Outcomes

Center for Neurologic Study - Lability Scale (CNS-LS) Total Score

The Center for Neurologic Study-Lability Scale (CNS-LS) is a 7-item self report scale that assesses pseudobulbar affect (PBA) by measuring the perceived frequency of PBA episodes (laughing or crying). Each item is scored using a 5-point Likert scale, from 1 (applies never) to 5 (applies most of the time). Scores range from 5-35. The higher the score, the worse the PBA.

Time frame: Average between Screening Visit to Visit 3

ALS Functional Rating Scale- Revised (ALSFRS-R) Total Score

The ALSFRS-R is a quickly administered (5 min) ordinal rating scale used to determine a subject's assessment of their capability and independence in 12 functional activities. There are 12 questions, graded by the subject 0-4 (4 is normal). Score of 0 (worst) to 48 (best). Reflects speech and swallowing, fine motor skills, large motor skills, and breathing.

Time frame: Average between Screening Visit to Visit 3

Visual Analog Scale - Speech Scores

Visual analog scales are useful for measuring complex clinical events and offer the advantage of self-administration and responsiveness to change over time. The scales designed for this study inventory three domains of bulbar function: speech, swallowing and salivation (sialorrhea). For each of these, subjects score themselves by indicating their level of function on a scale of 1 (severe impairment) to 10 (normal). Scores range from 1 to 10; the higher the score, the more normal the function.